Guardian Bio
Dendritic cell-based platform for cancer therapy
Boston, United States · Founded 2022 · $598K raised
- Headquarters
- Boston, Massachusetts
- Employees
- 1–10
- Founded
- 2022
- Website
- guardian-bio.com
- Total Funding
- $598K
- Last Round
- $98K GrantNov 2023
- Rounds
- 2
About
Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.
Summary
Guardian Bio is a Biotech company based in Boston, United States, founded in 2022. It has raised $598K in total across 2 rounds, most recently a $98K Grant round in Nov 2023. Investors include Y Combinator Continuity Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
